The perioperative management of antithrombotic therapy: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition)

Chest

Volumn 133, Issue 6 SUPPL. 6, 2008, Pages 299S-339S

  Douketis, James D ^a   Berger, Peter B ^b   Dunn, Andrew S ^c   Jaffer, Amir K ^d   Spyropoulos, Alex C ^e   Becker, Richard C ^f   Ansell, Jack E ^g,h  

^a MCMASTER UNIVERSITY   (Canada)

^b GEISINGER MEDICAL CENTER   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^e LOVELACE MEDICAL CENTER   (United States)

^f DUKE UNIVERSITY   (United States)

^g BOSTON UNIVERSITY   (United States)

^h BOSTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Arterial thromboembolism; Aspirin; Bleeding; Bridging anticoagulation; Clopidogrel; Low molecular weight heparin; Oral anticoagulant; Perioperative; Stroke; Surgery; Unfractionated heparin; Venous thromboembolism; Vitamin K antagonist

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS DIPYRIDAMOLE; AMINOCAPROIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; APROTININ; BEMIPARIN; CELECOXIB; CILOSTAZOL; CLOPIDOGREL; CYCLOOXYGENASE 2 INHIBITOR; DALTEPARIN; ENOXAPARIN; FIBRINOGEN RECEPTOR ANTAGONIST; FONDAPARINUX; HEMOSTATIC AGENT; HEPARIN; IDRAPARINUX; LOW MOLECULAR WEIGHT HEPARIN; NONSTEROID ANTIINFLAMMATORY AGENT; PACLITAXEL; RAPAMYCIN; THROMBIN INHIBITOR; TICLOPIDINE; TINZAPARIN; TRANEXAMIC ACID; UNINDEXED DRUG; VITAMIN K GROUP; WARFARIN;

ANTICOAGULATION; BLEEDING; BRAIN DISEASE; CATARACT EXTRACTION; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTINUOUS INFUSION; CORONARY STENT; COST CONTROL; DENTAL SURGERY; DRUG COST; DRUG EFFICACY; DRUG ELUTING STENT; DRUG INTERMITTENT THERAPY; DRUG SAFETY; DRUG WITHDRAWAL; ELECTIVE SURGERY; EMERGENCY SURGERY; EVIDENCE BASED PRACTICE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEMOSTASIS; HIGH RISK PATIENT; HUMAN; INTERNATIONAL NORMALIZED RATIO; LOADING DRUG DOSE; LOW DRUG DOSE; MAJOR SURGERY; NEUTROPENIA; PARTIAL THROMBOPLASTIN TIME; PERIOPERATIVE PERIOD; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTHETIC VALVE THROMBOSIS; REVIEW; RISK BENEFIT ANALYSIS; SKIN SURGERY; STROKE; THROMBOEMBOLISM; VENOUS THROMBOEMBOLISM;

ASPIRIN; DOSE-RESPONSE RELATIONSHIP, DRUG; EVIDENCE-BASED MEDICINE; FIBRINOLYTIC AGENTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INJECTIONS, SUBCUTANEOUS; PERIOPERATIVE CARE; PLATELET AGGREGATION INHIBITORS; THROMBOLYTIC THERAPY; TICLOPIDINE; TREATMENT OUTCOME; VITAMIN K;

EID: 46049099373     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.08-0675     Document Type: Article

References (237)

1. Ansell JE. The perioperative management of warfarin therapy. Arch Intern Med 2003; 163:881-883
2. American Heart Association. Heart Disease and Stroke Statistics Update. Dallas, TX: American Heart Association, 2001
3. Go AS, Hylek EM, Borowsky LH, et al. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Ann Intern Med 1999; 131:927-934
4. White RH, Kaatz S, Douketis J, et al. Comparison of the 30-day incidence of ischemic stroke and bleeding after major surgery in patients with or without atrial fibrillation (AF). J Thromb Haemost 2007; 5(suppl 1):O-M-035
5. McKenna R. Abnormal coagulation in the postoperative period contributing to excessive bleeding. Med Clin North Am 2001; 85:1277-1310
6. Tinker JH, Tarhan S. Discontinuing anticoagulant therapy in surgical patients with cardiac valve prostheses: observations in 180 operations. JAMA 1978; 239:738-739
7. Katholi RE, Nolan SP, McGuire LB. The management of anticoagulation during noncardiac operations in patients with prosthetic heart valves: a prospective study. Am Heart J 1978; 96:163-165
8. Torn M, Rosendaal FR. Oral anticoagulation in surgical procedures: risks and recommendations. Br J Haematol 2003; 123:676-682
9. Anonymous. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet 2000; 355:1295-1302
10. Dunn AS, Turpie AG. Perioperative management of patients receiving oral anticoagulants: a systematic review. Arch Intern Med 2003; 163:901-908
11. Kaplan RC, Tirschwell DL, Longstreth WT Jr, et al. Vascular events, mortality, and preventive therapy following ischemic stroke in the elderly. Neurology 2005; 65:835-842
12. Longstreth WT Jr, Bernick C, Fitzpatrick A, et al. Frequency and predictors of stroke death in 5,888 participants in the Cardiovascular Health Study. Neurology 2001; 56: 368-375
13. Martinelli J, Jiminez A, Rabago G, et al. Mechanical cardiac valve thrombosis: is thrombectomy justified? Circulation 1991; 84(suppl):70S-75S
14. Kini AS, Lee P, Marmur JD, et al. Correlation of postpercutaneous coronary intervention creatine kinase-MB and troponin I elevation in predicting mid-term mortality. Am J Cardiol 2004; 93:18-23
15. Landesberg G, Einav S, Christopherson R, et al. Perioperative ischemia and cardiac complications in major vascular surgery: importance of the preoperative twelve-lead electrocardiogram. J Vasc Surg 1997; 26:570-578
16. Stone GW, Aronow HD. Long-term care after percutaneous coronary intervention: focus on the role of antiplatelet therapy. Mayo Clin Proc 2006; 81:641-652
17. Popma JJ, Berger P, Ohman EM, et al. Antithrombotic therapy during percutaneous coronary intervention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126(suppl):576S-599S
18. Yang X, Alexander KP, Chen AY, et al. The implications of blood transfusions for patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE National Quality Improvement Initiative. J Am Coll Cardiol 2005; 46:1490-1495
19. Linkins LA, Choi PT, Douketis JD. Clinical impact of bleeding in patients taking oral anticoagulant therapy for VTE: a meta-analysis. Ann Intern Med 2003; 139:893-900
20. Rao SV, Jollis JG, Harrington RA, et al. Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA 2004; 292:1555-1562
21. Douketis JD, Johnson JA, Turpie AG. Low-molecular-weight heparin as bridging anticoagulation during interruption of warfarin: assessment of a standardized periprocedural anticoagulation regimen. Arch Intern Med 2004; 164:1319-1326
22. Kovacs MJ, Kearon C, Rodger M, et al. Single-arm study of bridging therapy with low-molecular-weight heparin for patients at risk of arterial embolism who require temporary interruption of warfarin. Circulation 2004; 110:1658-1663
23. Dagi TF. The management of postoperative bleeding. Surg Clin North Am 2005; 85:1191-1213
24. Litaker D. Preoperative screening. Med Clin North Am 1999; 83:1565-1581
25. Jones HU, Muhlestein JB, Jones KW, et al. Preoperative use of enoxaparin compared with unfractionated heparin increases the incidence of re-exploration for postoperative bleeding after open-heart surgery in patients who present with an acute coronary syndrome: clinical investigation and reports. Circulation 2002; 106:I19-I22
26. Mangano DT. Multicenter Study of Perioperative Ischemia Research: aspirin and mortality from coronary bypass surgery. N Engl J Med 2002; 347:1309-1317
27. Lazio BE, Sumard JM. Anticoagulation in neurosurgical patients. Neurosurgery 1999; 45:838-847
28. Patterson BM, Marchand R, Ranawat C. Complications of heparin therapy after total joint arthroplasty. J Bone Joint Surg Am 1989; 71:1130-1134
29. Hoy E, Granick M, Benevenia J, et al. Reconstruction of musculoskeletal defects following oncologic resection in 76 patients. Ann Plast Surg 2006; 57:190-194
30. Nielson JD, Gram J, Holm-Nielsen A, et al. Postoperative blood loss after transurethral prostatectomy is dependent on in-situ fibrinolysis. Br J Urol 1997; 889-893
31. Watson CJ, Deane AM, Doyle PT, et al. Identifiable factors in post-prostatectomy haemorrhage: the role of aspirin. Br J Urol 1990; 66:85-87
32. Sorbi D, Norton I, Conio M, et al. Postpolypectomy lower GI bleeding: descriptive analysis. Gastrointest Endosc 2000; 51:690-696
33. Ihezue CU, Smart J, Dewbury KC, et al. Biopsy of the prostate guided by transrectal ultrasound: relation between warfarin use and incidence of bleeding complications. Clin Radiol 2005; 60:459-463
34. Wiegand UK, LeJeune D, Boguschewski F, et al. Pocket hematoma after pacemaker or implantable cardioverter defibrillator surgery: influence of patient morbidity, operation strategy, and perioperative antiplatelet/ anticoagulation therapy. Chest 2004; 126:1177-1186
35. Wessler S, Gitel SN. Pharmacology of heparin and warfarin. J Am Coll Cardiol 1986; 8:10B-20B
36. Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126(suppl):188S-203S
37. Pedersen AK, FitzGerald GA. Dose-related kinetics of aspirin: presystemic acetylation of platelet cyclooxygenase. N Engl J Med 1984; 311:1206-1211
38. Savcic M, Hauert J, Bachmann F, et al. Clopidogrel loading dose regimens: kinetic profile of pharmacodynamic response in healthy subjects. Semin Thromb Haemost 1999; 25(suppl 2):15-19
39. Dunn AS, Spyropoulos A, Turpie AG. Bridging therapy in patients on long-term oral anticoagulants who require surgery: the Prospective Peri-operative Enoxaparin Cohort Trial (PROSPECT). J Thromb Haemost 2007; 5:2211-2218
40. Turpie AG, Douketis JD. Enoxaparin is effective and safe as bridging anticoagulation in patients with a mechanical prosthetic heart valve who reqire temporary interruption of warfarin because of surgery or an invasive procedure [abstract]. Blood 2004; 104:202A
41. Carrel TP, Klingenmann W, Mohacsi PJ, et al. Perioperative bleeding and thromboembolic risk during non-cardiac surgery in patients with mechanical prosthetic heart valves: an institutional review. J Heart Valve Dis 1999; 8:392-398
42. Larson BJ, Zumberg MS, Kitchens CS. A feasibility study of continuing dose-reduced warfarin for invasive procedures in patients with high thromboembolic risk. Chest 2005; 127: 922-927
43. White RH, McKittrick T, Hutchinson R, et al. Temporary discontinuation of warfarin therapy: changes in the international normalized ratio. Ann Intern Med 1995; 122:40-42
44. Palareti G, Legnani C. Warfarin withdrawal: pharmacokinetic- pharmacodynamic considerations. Clin Pharmacokinet 1996; 30:300-313
45. Salem DN, Stein PD, Al-Ahmad A, et al. Antithrombotic therapy in valvular heart disease-native and prosthetic: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126(suppl):457S-482S
46. Hylek EM, Regan S, Go AS, et al. Clinical predictors of prolonged delay in return of the international normalized ratio to within the therapeutic range after excessive anticoagulation with warfarin. Ann Intern Med 2001; 135:393-400
47. Gadisseur AP, van der Meer FJ, Adriaansen HJ, et al. Therapeutic quality control of oral anticoagulant therapy comparing the short-acting acenocoumarol and the long-acting phenprocoumon. Br J Haematol 2002; 117:940-946
48. Marietta M, Bertesi M, Simoni L, et al. A simple and safe nomogram for the management of oral anticoagulation prior to minor surgery. Clin Lab Haematol 2003; 25:127-130
49. Deerhake JP, Merz JC, Cooper JV, et al. The duration of anticoagulation bridging therapy in clinical practice may significantly exceed that observed in clinical trials. J Thromb Thrombolysis 2007; 23:107-113
50. Woods K, Douketis JD, Kathirgamanathan K, et al. Low-dose oral vitamin K to normalize the international normalized ratio prior to surgery in patients who require temporary interruption of warfarin. J Thromb Thrombolysis 2007; 24:93-97
51. Cannegieter SC, Rosendaal FR, Briet I. Thromboembolic and bleeding complications in patients with medical mechanical heart valve prostheses. Circulation 1994; 94:635-641
52. Herin D, Piper C, Bergemann R, et al. Thromboembolic and bleeding complications following St. Jude medical valve replacement: results of the German Experience with Low-Intensity Anticoagulation Study. Chest 2005; 127:53-59
53. Tominaga R, Kurisu K, Ochiai Y, et al. A 10-year experience with the Carbomedics cardiac prosthesis. Ann Thorac Surg 2005; 79:784-789
54. Galla JM, Fuhs BE. Outpatient anticoagulation protocol for mechanical valve recipients undergoing non-cardiac surgery [abstract]. J Am Coll Cardiol 2000; 35:531A
55. Spyropoulos AC, Turpie AGG, Dunn AS, et al. Clinical outcomes with unfractionated heparin or low-molecular-weight heparin as bridging therapy in patients on long-term oral anticoagulants: the REGIMEN registry. J Thromb Haemost 2006; 4:1246-1252
56. Ferreira I, Dos L, Tornos P, et al. Experience with enoxaparin in patients with mechanical heart valves who must withhold acenocumarol. Heart 2003; 89:527-530
57. Jaffer AK, Ahmed M, Brotman DJ, et al. Low-molecular-weight-heparins as periprocedural anticoagulation for patients on long-term warfarin therapy: a standardized bridging therapy protocol. J Thromb Thrombolysis 2005; 20: 11-16
58. Hammerstingl C, Tripp C, Schmidt H, et al. Periprocedural bridging therapy with low-molecular-weight heparin in chronically anticoagulated patients with prosthetic mechanical heart valves: experience in 116 patients from the prospective BRAVE registry. J Heart Valve Dis 2007; 16; 285-292
59. Santamaria MA, Mateo J, Pujol N, et al. Management of anticoagulation in patients who require colonoscopy or gastroscopy: saftey and efficacy of sodic bemiparin [Hibor] [abstract]. Blood 2004; 105:4060
60. Spandorfer JM, Lynch S, Weitz HH, et al. Use of enoxaparin for the chronically anticoagulated patient before and after procedures. Am J Cardiol 1999; 84:478-480
61. Tinmouth AH, Morrow BH, Cruickshank MK, et al. Dalteparin as periprocedure anticoagulation for patients on warfarin and at high risk of thrombosis. Ann Pharmacother 2001; 35:669-674
62. Wilson S, Morgan J, Gray L, et al. A model for perioperative outpatient management of anticoagulation in high-risk patients: an evaluation of effectiveness and safety. Can J Hosp Pharm 2001; 54:269-277
63. Malato A, Anastasio R, Cigna V, et al. Perioperative bridging therapy with low molecular weight heparin in patients requiring interruption of long-term oral anticoagulant therapy. Haematologica 2006; 91:10
64. Constans M, Santamaria A, Mateo J, et al. Low-molecular-weight heparin as bridging therapy during interruption of oral anticoagulation in patients who require colonoscopy or gastroscopy. Int J Clin Pract 2007; 61:212-217
65. Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126(suppl):338S-400S
66. Kearon C, Hirsh J. Management of anticoagulation before and after elective surgery. N Engl J Med 1997; 336:1506-1511
67. Baudet EM, Oca CC, Roques XF, et al. A 5/12 year experience with the St. Jude Medical cardiac valve prosthesis: early and late results of 737 valve replacements in 671 patients. J Thorac Cardiovasc Surg 1985; 90:137-144
68. Hart RG, Benavente O, McBride R, et al. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999; 131:492-501
69. Pearce LA, Hart RG, Halperin JL. Assessment of three schemes for stratifying stroke risk in patients with nonvalvular atrial fibrillation. Am J Med 2000; 109:45-51
70. Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001; 285:2864-2870
71. Gage BF, Van Walraven C, Pearce L, et al. Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. Circulation 2004; 110:2287-2292
72. Baudo F, de Cataldo F, Mostarda G, et al. Management of patients on long-term oral anticoagulant therapy undergoing elective surgery: survey of the clinical practice in the Italian anticoagulation clinics. Intern Emerg Med 2007; 2:280-284
73. Garcia DA, Regan S, Henault L, et al. Risk of thromboembolism with short-term interruption of warfarin therapy Arch Intern Med 2008; 168:63-69
74. Blacker DJ, Wijdicks EF, McClelland RL. Stroke risk in anticoagulated patients with atrial fibrillation undergoing endoscopy. Neurology 2003; 61:964-968
75. Douketis JD, Gu CS, Schulman S, et al. The risk of fatal pulmonary embolism after stopping anticoagulant therapy in patients with VTE. Ann Intern Med 2007; 147:766-774
76. Douketis JD, Kearon C, Bates S, et al. The risk of fatal pulmonary embolism in patients with treated venous thromboembolism. JAMA 1998; 279:458-462
77. Douketis JD, Foster GA, Crowther MA, et al. Clinical risk factors and timing of recurrent venous thromboembolism during the initial 3 months of anticoagulant therapy. Arch Intern Med 2000; 160:3431-3436
78. Kyrle PA, Eichinger S. Deep vein thrombosis. Lancet 2005; 365:1163-1174
79. White R. The epidemiology of venous thromboembolism. Circulation 2003; 107(suppl 1):14-18
80. Spyropoulos AC, Dunn A, Turpie AG, et al. Perioperative bridging therapy with unfractionated heparin or low-molecular-weight heparin in patients with mechanical heart valves on long-term oral anticoagulatns: results from the REGIMEN registry [abstract]. J Am Coll Cardiol 2005;45:352A
81. Halbritter KM, Wawer A, Beyer J, et al. Bridging anticoagulation for patients on long-term vitamin-K-antagonists: a prospective 1 year registry of 311 episodes. J Thromb Haemost 2007; 3:2823-2825
82. Eckman MH, Beshansky JR, Durand-Zaleski I, et al. Anticoagulation for noncardiac procedures in patients with prosthetic heart valves. Does low risk mean high cost? JAMA 1990; 263:1513-1521
83. Katholi RE, Nolan SP, McGuire LB. Living with prosthetic heart valves: subsequent noncardiac operations and the risk of thromboembolism or hemorrhage. Am Heart J 1976; 92:162-167
84. Douketis JD, Crowther MA, Cherian SS. Perioperative anticoagulation in patients with chronic atrial fibrillation who are undergoing elective surgery: results of a physician survey. Can J Cardiol 2000; 16:326-330
85. Douketis JD, Crowther MA, Cherian SS, et al. Physician preferences for perioperative anticoagulation in patients with a mechanical heart valve who are undergoing elective noncardiac surgery. Chest 1999; 116:1240-1246
86. Centers for Disease Control and Prevention. CDC Fact Book, 2001-2002. Atlanta, GA: Centers for Disease Control and Prevention, 2003
87. Kearon C, Ginsberg JS, Julian JA, et al. Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of VTE. JAMA 2006; 296:935-942
88. Hylek EM, Go AS, Chang Y, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003; 349:1019-1026
89. Hylek EM, Skates SJ, Sheehan MA, et al. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 1996; 335:540-546
90. O'Donnell M, Oczkowski W, Fang J, et al. Preadmission antithrombotic treatment and stroke severity in patients with atrial fibrillation and acute ischaemic stroke: an observational study. Lancet Neurol 2006; 5:749-754
91. Büller HR, Bousser MG, Bouthier J, et al. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial. Lancet 2008; 371: 278-280
92. Fanikos J, Tsilimingras K, Kucher N, et al. Comparison of efficacy, safety, and cost of low-molecular-weight heparin with continuous-infusion unfractionated heparin for initiation of anticoagulation after mechanical prosthetic valve implantation. Am J Cardiol 2004; 93:247-250
93. Amorosi SL, Tsilimingras K, Thompson D, et al. Cost analysis of 'bridging therapy' with low-molecular-weight heparin versus unfractionated heparin during temporary interruption of chronic anticoagulation. Am J Cardiol 2004; 93:509-511
94. Spyropoulos AC, Frost FJ, Hurley JS, et al. Costs and clinical outcomes associated with low-molecular-weight heparin vs unfractionated heparin for perioperative bridging in patients receiving long-term oral anticoagulant therapy. Chest 2004; 125:1642-1650
95. Spyropoulos AC, Jenkins P, Bornikova L. A disease management protocol for outpatient perioperative bridge therapy with enoxaparin in patients requiring temporary interruption of long-term oral anticoagulation. Pharmacotherapy 2004; 24:649-658
96. Goldstein JL Larson LR, Yamashita BD, et al. Low molecular weight heparin versus unfractionated heparin in the colonoscopy peri-procedure period: a cost modeling study. Am J Gastroenterol 2001; 96:2360-2366
97. Douketis JD, Woods K, Foster GA, et al. Bridging anticoagulation with low-molecular-weight heparin after interruption of warfarin therapy is associated with a residual anticoagulant effect prior to surgery. Thromb Haemost 2005; 94:528-531
98. O'Donnell MJ, Kearon C, Johnson J, et al. Preoperative anticoagulant activity after bridging low-molecular-weight heparin for temporary interruption of warfarin. Ann Intern Med 2007; 146:184-187
99. Turpie AG, Bauer KA, Eriksson BI, et al. Fondaparinux vs enoxaparin for the prevention of VTE in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med 2002; 162:1833-1840
100. Strebel N, Prins M, Agnelli G, et al. Preoperative or postoperative start of prophylaxis for VTE with low-molecular-weight heparin in elective hip surgery? Arch Intern Med 2002; 162:1451-1456
101. Cruickshank MK, Levine MN, Hirsh J, et al. A standard heparin nomogram for the management of heparin therapy. Arch Intern Med 1991; 151:333-337
102. Anand SS, Yusuf S, Pogue J, et al. Relationship of activated partial thromboplastin time to coronary events and bleeding in patients with acute coronary syndromes who receive heparin. Circulation 2003; 107:2884-2888
103. Dolovich LR, Ginsberg JS, Douketis JD, et al. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of VTE: examining some unanswered questions regarding location of treatment, product type, and dosing frequency. Arch Intern Med 2000; 160:181-188
104. Tricoci P, Roe MT, Mulgund J, et al. Clopidogrel to treat patients with non-ST-segment elevation acute coronary syndromes after hospital discharge. Arch Intern Med 2006; 166:806-811
105. Fox KA, Goodman SG, Anderson FA Jr, et al. From guidelines to clinical practice: the impact of hospital and geographical characteristics on temporal trends in the management of acute coronary syndromes; the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2003; 24:1414-1424
106. Berger JS, Roncaglioni MC, Avanzini F, et al. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA 2006; 295:306-313
107. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005; 293: 2126-2130
108. Patrono C, Coller B, FitzGerald GA, et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects; the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126(suppl):234S-264S
109. Roth GJ, Majerus PW. The mechanism of the effect of aspirin on human platelets: I. Acetylation of a particulate fraction protein. J Clin Invest 1975; 56:624-632
110. Roth GJ, Stanford N, Majerus PW. Acetylation of prostaglandin synthase by aspirin. Proc Natl Acad Sci U S A 1975; 72:3073-3076
111. Taggart DP, Siddiqui A, Wheatley DJ. Low-dose preoperative aspirin therapy, postoperative blood loss, and transfusion requirements. Ann Thorac Surg 1990; 50:424-428
112. Quinn MJ, Fitzgerald DJ. Ticlopidine and clopidogrel. Circulation 1999; 100:1667-1672
113. Harder S, Klinkhardt U, Alvarez JM. Avoidance of bleeding during surgery in patients receiving anticoagulant and/or antiplatelet therapy: pharmacokinetic and pharmacodynamic considerations. Clin Pharmacokinet 2004; 43:963-981
114. Caplain H, Cariou R. Long-term activity of clopidogrel: a three-month appraisal in healthy volunteers. Semin Thromb Haemost 1999; 25(suppl 2):21-24
115. Lenz TL, Hilleman DE. Aggrenox: a fixed-dose combination of aspirin and dipyridamole. Ann Pharmacother 2000; 34: 1283-1290
116. Douglas JS Jr, Holmes DR Jr, Kereiakes DJ, et al. Coronary stent restenosis in patients treated with cilostazol. Circulation 2005; 112:2826-2832
117. Thompson PD, Zimet R, Forbes WP, et al. Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication. Am J Cardiol 2002; 90:1314-1319
118. Schrör K. The pharmacology of cilostazol. Diabet Obes Metab 2002; 4(suppl 2):S14-S19
119. Münster T, Furst DE. Nonsteroidal anti-inflammatory drugs, disease-modifying antirheumatic drugs, nonopioid analgesics, and drugs used in gout. 8th ed. New York, NY: McGraw-Hill, 2001
120. Münster T, Furst DE. Pharmacotherapeutic strategies for disease-modifying antirheumatic drug (DMARD) combinations to treat rheumatoid arthritis (RA). Clin Exp Rheumatol 1999; 17(6 suppl 18):S29-S36
121. Quinn MJ, Fitzgerald DJ. Ticlopidine and clopidogrel. Circulation 1999; 100:1667-1672
122. Steinhubl SR, Lauer MS, Mukherjee DP, et al. The duration of pretreatment with ticlopidine prior to stenting is associated with the risk of procedure-related non-Q-wave myocardial infarctions. J Am Coll Cardiol 1998; 32:1366-1370
123. Schühlen H, Kastrati A, Dirschinger J, et al. Intracoronary stenting and risk for major adverse cardiac events during the first month. Circulation 1998; 98:104-111
124. Steinhubl SR, Berger PB, Brennan DM, et al. Optimal timing for the initiation of pre-treatment with 300 mg clopidogrel before percutaneous coronary intervention. J Am Coll Cardiol 2006; 47:939-943
125. Gawaz M, Seyfarth M, Muller I, et al. Comparison of effects of clopidogrel versus ticlopidine on platelet function in patients undergoing coronary stent placement. Am J Cardiol 2001; 87:332-336
126. Müller I, Seyfarth M, Rudiger S, et al. Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. Heart 2001; 85:92-93
127. Geiger J, Teichmann L, Grossmann R, et al. Monitoring of clopidogrel action: comparison of methods. Clin Chem 2005; 51:957-965
128. Steinhubl SR, Talley JD, Braden GA, et al. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study. Circulation 2001; 103:2572-2578
129. Kitchen L, Erichson RB, Sideropoulos H. Effect of drug-induced platelet dysfunction on surgical bleeding. Am J Surg 1982; 143:215-217
130. Ferraris VA, Swanson E. Aspirin usage and perioperative blood loss in patients undergoing unexpected operations. Surg Gynecol Obstet 1983; 156:439-442
131. Sharma AK, Ajani AE, Hamwi SM, et al. Major noncardiac surgery following coronary stenting: when is it safe to operate? Catheter Cardiovasc Interv 2004; 63:141-145
132. Reddy PR, Vaitkus PT. Risks of noncardiac surgery after coronary stenting. Am J Cardiol 2005; 95:755-757
133. Ernst A, Eberhardt R, Wahidi M, et al. Effect of routine clopidogrel use on bleeding complications after transbronchial biopsy in humans. Chest 2006; 129:734-737
134. Thom T, Haase N, Rosamond W, et al. Heart disease and stroke statistics-2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2006; 113:e85-e151
135. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345:494-502
136. Eikelboom JW, Mehta SR, Anand SS, et al. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 2006; 114:774-782
137. Koch CG, Li L, Duncan AI, et al. Morbidity and mortality risk associated with red blood cell and blood-component transfusion in isolated coronary artery bypass grafting. Crit Care Med 2006; 34:1608-1616
138. Sethi GK, Copeland JG, Goldman S, et al. Implications of preoperative administration of aspirin in patients undergoing coronary artery bypass grafting: Department of Veterans Affairs Cooperative Study on Antiplatelet Therapy. J Am Coll Cardiol 1990; 15:15-20
139. Merritt JC, Bhatt DL. The efficacy and safety of perioperative antiplatelet therapy. J Thromb Thrombolysis 2002; 13:97-103
140. Bybee KA, Powell BD, Valeti U, et al. Preoperative aspirin therapy is associated with improved postoperative outcomes www.chestjournal.org in patients undergoing coronary artery bypass grafting. Circulation 2005; 112:1286-1292
141. Topol E. Aspirin with bypass surgery: from taboo to new standard of care. N Engl J Med 2002; 347:1359-1360
142. Alexander JH, Berger PB, Hafley G, et al. Impact of early clopidogrel use on angiographic and clinical outcomes following coronary artery bypass surgery: findings from PREVENT IV. Am Coll Cardiol 2006; 47(suppl A):932-257
143. Mehta RH, Roe MT, Mulgund J, et al. Acute clopidogrel use and outcomes in patients with non-ST-segment elevation acute coronary syndromes undergoing coronary artery bypass surgery. J Am Coll Cardiol 2006; 48:281-286
144. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345:494-502
145. Eikelboom JW, Mehta SR, Anand SS, et al. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 2006; 114:774-782
146. Purkayastha S, Athanasiou T, Malinovski V, et al. Does clopidogrel affect outcome after coronary artery bypass grafting? A meta-analysis. Heart 2006; 92:531-532
147. Hongo RH, Ley J, Dick SE, et al. The effect of clopidogrel in combination with aspirin when given before coronary artery bypass grafting. J Am Coll Cardiol 2002; 40:231-237
148. Chen L, Bracey AW, Radovancevic R, et al. Clopidogrel and bleeding in patients undergoing elective coronary artery bypass surgery by intravenous aprotinin during cardiothoracic surgery. Circulation 2004; 110:2004
149. Kapetanakis EI, Medlam DA, Petro KR, et al. Effect of clopidogrel premedication in off-pump cardiac surgery: are we forfeiting the benefits of reduced hemorrhagic sequelae? Circulation 2006; 113:1667-1674
150. Akowuah E, Shrivastava V, Jamnadas B, et al. Comparison of two strategies for the management of antiplatelet therapy during urgent surgery. Ann Thorac Surg 2005; 1:149-152
151. van der Linden J, Lindvall G, Sartipy U. Aprotinin decreases postoperative bleeding and number of transfusions in patients on clopidogrel undergoing coronary artery bypass graft surgery: a double-blind, placebo-controlled, randomized clinical trial. Circulation 2005; 112(suppl I):276-280
152. Mangano DT, Tudor IC. The risk associated with aprotinin in cardiac surgery. N Engl J Med 2006; 254:353-365
153. Spiess BD, Royston D, Levy JH, et al. Platelet transfusions during coronary artery bypass graft surgery are associated with serious adverse outcomes. Transfusion 2004; 44:1143-1148
154. Carless PA, Moxey AJ, Stokes BJ, et al. Are antifibrinolytic drugs equivalent in reducing blood loss and transfusion in cardiac surgery? A meta-analysis of randomized head-to-head trials. BMC Cardiovasc Disord 2005; 5:19
155. Brown JR, Birkmeyer NJ, O'Connor GT. Meta-analysis comparing the effectiveness and adverse outcomes of antifibrinolytic agents in cardiac surgery. Circulation 2007; 115:2801-2813
156. Pleym H, Stenseth R, Wahba A, et al. Prophylactic treatment with desmopressin does not reduce postoperative bleeding after coronary surgery in patients treated with aspirin before surgery. Anesth Analg 2004; 98:578-584
157. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358:527-533
158. Sabatine MS, Cannon CP, Gibson CM, et al. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction: the PCI-CLARITY Study. JAMA 2005; 294:1224-1232
159. Kastrati A, von Beckerath N, Joost A, et al. Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy. Circulation 2004; 110:1916-1919
160. Patti G, Colonna G, Pasceri V, et al. A randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) Study. Circulation 2005; 111:2099-2106
161. Kastrati A, Mehilli J, Schulhen H, et al. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N Engl J Med 2004; 350:232-238
162. Hausleiter J, Kastrati A, Mehilli J, et al. A randomized trial comparing phosphorylcholine-coated stenting with balloon angioplasty as well as abciximab with placebo for restenosis reduction in small coronary arteries. J Intern Med 2004; 256:388-397
163. Kaluza GL, Joseph J, Lee JR, et al. Catastrophic outcomes of noncardiac surgery soon after coronary stenting. J Am Coll Cardiol 2000; 35:1288-1294
164. Wilson SH, Fasseas P, Orford JL, et al. Clinical outcome of patients undergoing non-cardiac surgery in the two months following coronary stenting. J Am Coll Cardiol 2003; 42: 234-240
165. Vicenzi MN, Meislitzer T, Heitzinger B, et al. Coronary artery stenting and non-cardiac surgery: a prospective outcome study. Br J Anaesth 2006; 96:686-693
166. McFadden EP, Stabile E, Regar E, et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 2004; 364:1519-1521
167. Nasser M, Kapeliovich M, Markiewicz W. Late thrombosis of sirolimus-cluting stents following noncardiac surgery. Catheter Cardiovasc Interv 2005; 65:516-519
168. Compton PA, Zankar AA, Adesanya AO, et al. Risk of noncardiac surgery after coronary drug-eluting stent implantation. Am J Cardiol 2006; 98:1212-1213
169. Bakhru M, Saber W, Brotman D, et al. Is discontinuation of antiplatelet therapy after 6 months safe in patients with drug-eluting stents undergoing noncardiac surgery? Cleve Clin J Med 2006; 73:S23
170. Fleron MH, Dupuis M, Mottet P, et al. Non cardiac surgery in a patient with coronary stenting: think sirolimus now! Ann Fr Anesth Reanim 2003; 22:733-735
171. Collet JP, Montalescot G, Blanchet B, et al. Impact of prior use of recent withdrawal of oral antiplatelet agents on acute coronary syndromes. Circulation 2004; 110:2361-2367
172. Ferrari E, Benhamou M, Cerboni P, et al. Coronary syndromes following aspiring withdrawal: a special risk for late stent thrombosis. J Am Coll Cardiol 2005; 45:456-459
173. Wilson S, Rihal CS, Bell MR, et al. Timing of coronary stent thrombosis in patients treated with ticlopidine and aspirin. Am J Cardiol 1999; 83:1006-1011
174. Cutlip DE, Baim DS, Ho KK, et al. Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials. Circulation 2001; 103:1967-1971
175. Schouten O, Bax JJ, Poldermans D. Management of patients with cardiac stents undergoing noncardiac surgery. Curr Opin Anaesthesiol 2007; 20:274-278
176. Bergerson P, Rudondy P, Poyen V, et al. Long-term peripheral stent evaluation using angioscopy. Int Angiol 1991; 10:182-186
177. Ueda Y, Nanto S, Komamura K, et al. Neointimal coverage of stents in human coronary arteries observed by angioscopy. J Am Coll Cardiol 1994; 23:341-346
178. Cattaneo M. Platelet P2 receptors: old and new targets for antithrombotic drugs. Expert Rev Cardiovasc Ther 2007; 5:45-55
179. Grines CL, Bonow RO, Casey DE Jr, et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. J Am Coll Cardiol 2007; 49:734-739
180. Brilakis ES, Banerjee S, Berger PB. Perioperative management of patients with coronary stents. J Am Coll Cardiol 2007; 49:2145-2150
181. Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3:692-694
182. Borea G, Montebugnoli L, Capuzzi P, et al. Tranexamic acid as a mouthwash in anticoagulant-treated patients undergoing oral surgery: an alternative method to discontinuing anticoagulant therapy. Oral Surg Oral Med Oral Pathol 1993; 75:29-31
183. Evans IL, Sayers MS, Gibbons AJ, et al. Can warfarin be continued during dental extraction? Results of a randomized controlled trial. Br J Oral Maxillofac Surg 2002; 40:248-252
184. Sacco R, Sacco M, Carpenedo M, et al. Oral surgery in patients on oral anticoagulant therapy: a randomized comparison of different INR targets. J Thromb Haemost 2006; 4:688-689
185. Al-Belasy FA, Amer MZ. Hemostatic effect of n-butyl-2-cvanoacrylate (histoacryl) glue in warfarin-treated patients undergoing oral surgery. J Oral Maxillofac Surg 2003; 61:1405-1409
186. Carter G, Goss A. Tranexamic acid mouthwash - a prospective randomized study of a 2-day regimen vs 5-day regimen to prevent postoperative bleeding in anticoagulated patients requiring dental extractions. Int J Oral Maxillofac Surg 2003; 32:504-507
187. Carter G, Goss A, Lloyd J, et al. Tranexamic acid mouthwash versus autologous fibrin glue in patients taking warfarin undergoing dental extractions: a randomized prospective clinical study. J Oral Maxillofac Surg 2003; 61:1432-1435
188. Halfpenny W, Fraser JS, Adlam DM. Comparison of 2 hemostatic agents for the prevention of postextraction hemorrhage in patients on anticoagulants. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001; 92:257-259
189. Ramström G, Sindet-Pedersen S, Hall G, et al. Prevention of postsurgical bleeding in oral surgery using tranexamic acid without dose modification of oral anticoagulants. J Oral Maxillofac Surg 1993; 51:1211-1216
190. Campbell JH, Alvarado F, Murray RA. Anticoagulation and minor oral surgery: should the anticoagulation regimen be altered? J Oral Maxillofac Surg 2000; 58:131-135
191. Cannon PD, Dharmar VT. Minor oral surgical procedures in patients on oral anticoagulants: a controlled study. Aust Dent J 2003; 48:115-118
192. Devani P, Lavery KM, Howell CJ. Dental extractions in patients on warfarin: is alteration of anticoagulant regime necessary? Br J Oral Maxillofac Surg 1998; 36:107-111
193. Gaspar R, Brenner B, Ardekian L, et al. Use of tranexamic acid mouthwash to prevent postoperative bleeding in oral surgery patients on oral anticoagulant medication. Quintessence Int 1997; 28:375-379
194. Saour JN, Ali HA, Mammo LA, et al. Dental procedures in patients receiving oral anticoagulation therapy. J Heart Valve Dis 1994; 3:315-317
195. Street AM, Leung W. Use of tranexamic acid mouthwash in dental procedures in patients taking oral anticoagulants. Med J Aust 1990; 153:630
196. Zanon E, Martinelli F, Bacci C, et al. Safety of dental extraction among consecutive patients on oral anticoagulant treatment managed using a specific dental management protocol. Blood Coagul Fibrinolysis 2003; 14:27-30
197. Blinder D, Manor Y, Martinowitz U, et al. Dental extractions in patients maintained on oral anticoagulant therapy: comparison of INR value with occurrence of postoperative bleeding. Int J Oral Maxillofac Surg 2001; 30:518-521
198. Della Valle A, Sammartino G, Marenzi G, et al. Prevention of postoperative bleeding in anticoagulated patients undergoing oral surgery: use of platelet-rich plasma gel. J Oral Maxillofac Surg 2003; 61:1275-1278
199. Martinowitz U, Mazar AL, Taicher S, et al. Dental extraction for patients on oral anticoagulant therapy. Oral Surg Oral Med Oral Pathol 1990; 70:274-277
200. Ramli R, Abdul Rahman R. Minor oral surgery in anticoagulated patients: local measures alone are sufficient for haemostasis. Singapore Dent J 2005; 27:13-16
201. Russo G, Corso LD, Biasiolo A, et al. Simple and safe method to prepare patients with prosthetic heart valves for surgical dental procedures. Clin Appl Thromb Haemost 2000; 6:90-93
202. Zusman SP, Lustig JP, Baston I. Postextraction hemostasis in patients on anticoagulant therapy: the use of a fibrin sealant. Quintessence Int 1992; 23:713-716
203. Barrero MV, Knezevic M, Martín MT. Oral surgery in the patients undergoing oral anticoagulant therapy. Medicina Oral 2002; 7:63-70
204. Cieslik-Bielecka A, Pelc R, Cieslik T. Oral surgery procedures in patients on anticoagulants: preliminary report. Kardiologia Polska 2005; 63:137-140
205. Keiani Motlagh K, Loeb I, Legrand W, et al. Prevention of postoperative bleeding in patients taking oral anticoagulants: effects of tranexamic acid. Rev Stomatol Chir Maxillofac 2003; 104:77-79
206. Garcia-Darennes F, Darennes J, Freidel M, et al. Protocol for adapting treatment with vitamin K antagonists before dental extraction. Rev Stomatol Chir Maxillofac 2003; 104:69-72
207. Blinder D, Manor Y, Martinowitz U, et al. Dental extractions in patients maintained on continued oral anticoagulant: comparison of local hemostatic modalities. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1999; 88:137-140
208. Bodner L, Weinstein JM, Baumgarten AK. Efficacy of fibrin sealant in patients on various levels of oral anticoagulant undergoing oral surgery. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1998; 86:421-424
209. Ardekian L, Gaspar R, Peled M, et al. Does low-dose aspirin therapy complicate oral surgical procedures? J Am Dent Assoc 2000; 131:331-335
210. Madan GA, Madan SG, Madan G, et al. Minor oral surgery without stopping daily low-dose aspirin therapy: a study of 51 patients. J Oral Maxillofac Surg 2005; 63:1262-1265
211. Allard RH, Baart JA, Huijgens PC, et al. Antithrombotic therapy and dental surgery with bleeding. Ned Tijdschr Tandheelkd 2004; 111:482-485
212. Alcalay J. Cutaneous surgery in patients receiving warfarin therapy. Dermatol Surg 2001; 27:756-758
213. Billingsley EM, Maloney ME. Intraoperative and postoperative bleeding problems in patients taking warfarin, aspirin, and nonsteroidal antiinflammatory agents: a prospective study. Dermatol Surg 1997; 23:381-383
214. Kargi E, Babuccu O, Hosnuter M, et al. Complications of minor cutaneous surgery in patients under anticoagulant treatment. Aesthetic Plast Surg 2002; 26:483-485
215. Syed S, Adams BB, Liao W, et al. A prospective assessment of bleeding and international normalized ratio in warfarin-anticoagulated patients having cutaneous surgery. J Am Acad Dermatol 2004; 51:955-957
216. Bartlett GR. Does aspirin affect the outcome of minor cutaneous surgery? Br J Plast Surg 1999; 52:214-216
217. Shalom A, Wong L. Outcome of aspirin use during excision of cutaneous lesions. Ann Plast Surg 2003; 50:296-298
218. Alam M, Goldberg LH. Serious adverse vascular events associated with perioperative interruption of antiplatelet and anticoagulant therapy. Dermatol Surg 2002; 28:992-998
219. Hirschman DR, Morby LJ. A study of the safety of continued anticoagulation for cataract surgery patients. Nurs Forum 2006; 41:30-37
220. Kallio H, Paloheimo M, Maunuksela EL. Haemorrhage and risk factors associated with retrobulbar/peribulbar block: a prospective study in 1383 patients. Br J Anaesth 2000; 85:708-711
221. Katz J, Feldman MA, Bass EB, et al. Risks and benefits of anticoagulant and antiplatelet medication use before cataract surgery. Ophthalmology 2003; 110:1784-1788
222. Lumme P, Laatikainen LT. Risk factors for intraoperative and early postoperative complications in extracapsular cataract surgery. Eur J Ophthalmol 1994; 4:151-158
223. Narendran N, Williamson TH. The effects of aspirin and warfarin therapy on haemorrhage in vitreoretinal surgery. Acta Ophthalmol Scand 2003; 81:38-40
224. Wirbelauer C, Weller A, Haberle H, et al. Cataract surgery under topical anesthesia with oral anticoagulants. Klin Monatsbl Augenheilkd 2004; 221:749-752
225. Roberts CW, Woods SM, Turner LS. Cataract surgery in anticoagulated patients. J Cataract Refract Surg 1991; 17: 309-312
226. Rotenstreich Y, Rubowitz A, Segev F, et al. Effect of warfarin therapy on bleeding during cataract surgery. J Cataract Refract Surg 2001; 27:1344-1346
227. Kumar N, Jivan S, Thomas P, et al. Sub-Tenon's anesthesia with aspirin, warfarin, and clopidogrel. J Cataract Refract Surg 2006; 32:1022-1025
228. Davies B. Combined aspirin and clopidogrel in cataract surgical patients: a new risk factor for ocular haemorrhage? Br J Ophthalmol 2004; 88:1226-1227
229. Baker RI, Coughlin PB, Gallus AS, et al. Warfarin reversal: consensus guidelines, on behalf of the Australasian Society of Thrombosis and Haemostasis. Med J Aust 2004; 181:492-497
230. Dezee KJ, Shimeall WT, Douglas KM, et al. Treatment of excessive anticoagulation with phytodione (vitamin K): a meta-analysis. Arch Intern Med 2006; 166:391-397
231. Lubetsky A, Yonath H, Olchovsky D, et al. Comparison of oral vs intravenous phytodione (vitamin K1) in patients with excessive anticoagulation: a prospective randomized controlled study. Arch Intern Med 2003; 163:2469-2473
232. Raj G, Kumar R, McKinney WP. Time course of reversal of anticoagulant effect of warfarin by intravenous and subcutaneous phytodione. Arch Intern Med 2000; 159:2721-2724
233. Hongo RH, Ley J, Dick SE, et al. The effect of clopidogrel in combination with aspirin when given before coronary artery bypass grafting. J Am Coll Cardiol 2002; 40:231-237
234. Vilahur G, Choi BG, Zafar MU, et al. Normalization of platelet reactivity in clopidogrel-treated subjects. J Thromb Haemost 2007; 5:82-90
235. Levi MM, Vink R, de Jonge E. Management of bleeding disorders by prohemostatic therapy. Int J Hematol 2002; 76(suppl 2):139-144
236. Porte RJ, Leebeek FW. Pharmacological strategies to decrease transfusion requirements in patients undergoing surgery. Drugs 2002; 62:2193-2211
237. Nutescu E, Helgason C. Outpatient dalteparin peri-procedure bridge therapy in patients maintained on long term warfarin. Stroke 2001; 32:328-329